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Background: Patients with bone metastases from non-small cell lung 
cancer (NSCLC) may experience potentially disabling skeletal-related 
events (SREs) such as pathologic fracture, spinal cord compression, 
bone pain requiring palliative radiotherapy, orthopedic surgery, and 
hypercalcemia of malignancy. Most patients with bone metastases from 
NSCLC experience at least 1 SRE. Over a patient’s lifetime, multiple 
SREs may occur. Therefore, prevention of SREs is important to prevent 
the loss of patients’ functional independence. Zoledronic acid (ZOL) 
can reduce the risk of SREs in patients with bone metastases from solid 
tumors. We evaluated whether ZOL can reduce the burden of skeletal 
morbidity to patients with NSCLC using data from a large, randomized, 
placebo-controlled trial in patients with bone metastases from NSCLC 
or other solid tumors.
Methods: A retrospective evaluation of SREs was performed on 
patients with NSCLC who were randomized to treatment with either 
ZOL or placebo for up to 21 months (n = 378). All patients received 
concomitant antineoplastic therapy. Skeletal morbidity in the ﬁrst 6 
months on study was analyzed using a robust, survival-adjusted cumu-
lative mean function. 
Results: Patient demographics and baseline disease characteristics 
were similar between groups. The mean time from diagnosis of bone 
metastases to study entry was approximately 4 months, and approxi-
mately 70% of patients experienced an SRE before study entry. An 
evaluation of the ﬁrst 6 months of this study showed that in the placebo 
group, approximately 50% of patients experienced a ﬁrst on-study 
SRE (Figure 1), approximately 20% of whom went on to experience a 
second SRE. Moreover, some patients experienced a third event within 
this time period. Zoledronic acid not only reduced the incidence of ﬁrst 
on-study SREs, but also reduced the incidence of subsequent events in 
patients with NSCLC. Although this study was not statistically powered 
to evaluate differences for this endpoint, there was a clearly reduced 
rate of events for ZOL compared with placebo. 
Conclusions: The results of these analyses show that within a 6-month 
treatment period, ZOL reduced the incidence of a ﬁrst and subsequent 
SRE compared with placebo in patients with bone metastases from 
NSCLC. These analyses illustrate the fact that ZOL reduces skeletal 
morbidity and may therefore preserve quality of life and functional 
independence in patients with bone metastases from NSCLC.
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Background: Polo-like kinase 1 (Plk1), a key regulator of cell cycle 
progression and accurate spindle assembly, represents an attractive 
target for cancer drug development as it is highly expressed in malig-
nant cells and serves as a prognostic marker in certain human cancer 
types. We have previously shown that BI 2536, a potent and selective 
small-molecule inhibitor of Plk1, induces a characteristic mitotic arrest 
phenotype (“Polo-arrest”) and subsequent apoptosis in human cancer 
cells and is highly efﬁcacious in nude mouse xenograft models of 
human cancer at well-tolerated doses. BI 2536, the ﬁrst speciﬁc Plk1 
inhibitor in clinical development, has demonstrated encouraging results 
in phase I trials. This study was designed to examine the efﬁcacy of BI 
2536 in various models of NSCLC in vivo. 
Methods: The human NSCLC cell lines NCI-H460, NCI-H520TC, 
Calu-6 and A549 were used to evaluate the anti-tumor effects of BI 
2536. Cell proliferation in vitro was assessed using Alamar Blue 
assays. For in vivo studies, nude mice bearing subcutaneous human 
tumor xenografts were treated intravenously with 40 or 50 mg/kg of BI 
2536 given i.v. once or twice weekly for 2 to 7 weeks; control animals 
were injected with vehicle only. To assess the therapeutic potential of 
BI 2536 in combination with established chemotherapeutic agents, 
docetaxel (15 mg/kg once weekly i.v.), cisplatin (5 mg/kg once weekly 
i.p.) or pemetrexed (150 mg/kg i.p. on 5 consecutive days) were admin-
istered together with BI 2536. Efﬁcacy was determined by measuring 
tumor volumes and tolerability of treatment was assessed by determin-
ing clinical signs and body weight 3 times a week.
